Weiss Amir reported option exercise involving 7,755 derivative units of TEVA PHARMACEUTICAL INDUSTRIES LTD at $0.00 for $0 on Nov 9, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Accounting Officer
Chief Accounting Officer
Filed Nov 12, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
7,755Stock Options (right to buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
0Direct
Trade date
Nov 9, 2026Option exercise
Filed
Nov 12, 2026, 4:10 PM ET3-day reporting delay
Accession
0001193125-26-458383Code M · Transaction 398810
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 9, 2026Option exercise7,755$34.70$269,098.50Trade 398806
Nov 9, 2026Sell662$43.15−$28,565.30Trade 398807
Nov 9, 2026Sell7,093$43.03−$305,246.55Trade 398808
Nov 9, 2026Sell9,534$43.03−$410,237.53Trade 398809
5 transaction rows in this filing. Joint filers share the same rows.

TEVA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
TEVA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 19, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −5.8%1w ago −7%1d ago −2.4%
Returns since7d30d90d180d1y

Footnotes in full

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.02 to $43.05, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.025 to $43.04, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. F3: Stock options were granted on March 3, 2017, with 1,938 vested on each of March 3, 2018, March 3, 2019 and March 3, 2020, and 1,941 vested on March 3, 2021.